Wolfe Research Forecasts Strong Price Appreciation for Corteva (NYSE:CTVA) Stock

Corteva (NYSE:CTVA) had its price objective raised by research analysts at Wolfe Research from $81.00 to $86.00 in a research note issued on Thursday,MarketScreener reports. The firm currently has an “outperform” rating on the stock. Wolfe Research’s price target points to a potential upside of 18.00% from the stock’s current price.

Other research analysts have also recently issued reports about the company. JPMorgan Chase & Co. cut Corteva from an “overweight” rating to a “neutral” rating and raised their target price for the stock from $75.00 to $77.00 in a research report on Thursday. Wells Fargo & Company increased their target price on Corteva from $77.00 to $85.00 and gave the stock an “overweight” rating in a research report on Thursday. Oppenheimer set a $86.00 price objective on shares of Corteva in a report on Thursday. Rothschild & Co Redburn decreased their target price on Corteva from $71.00 to $65.00 and set a “neutral” rating on the stock in a research report on Tuesday, November 11th. Finally, Zacks Research raised shares of Corteva from a “hold” rating to a “strong-buy” rating in a research note on Thursday, January 22nd. Two analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and six have given a Hold rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $82.37.

Corteva Stock Up 0.6%

Shares of NYSE:CTVA opened at $72.88 on Thursday. Corteva has a 1 year low of $53.40 and a 1 year high of $77.41. The company has a debt-to-equity ratio of 0.07, a current ratio of 1.43 and a quick ratio of 1.07. The stock’s 50-day moving average is $68.72 and its 200 day moving average is $68.43. The company has a market cap of $49.25 billion, a PE ratio of 46.10, a P/E/G ratio of 1.86 and a beta of 0.75.

Corteva (NYSE:CTVA) last posted its quarterly earnings data on Tuesday, February 3rd. The company reported $0.22 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $0.22. The business had revenue of $3.91 billion during the quarter, compared to the consensus estimate of $4.23 billion. Corteva had a return on equity of 9.06% and a net margin of 6.29%.The firm’s quarterly revenue was down 1.7% compared to the same quarter last year. During the same quarter in the prior year, the company earned $0.32 earnings per share. Corteva has set its FY 2026 guidance at 3.450-3.700 EPS. Sell-side analysts anticipate that Corteva will post 2.96 EPS for the current year.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in CTVA. PNC Financial Services Group Inc. raised its holdings in Corteva by 1.5% in the 4th quarter. PNC Financial Services Group Inc. now owns 673,135 shares of the company’s stock worth $45,120,000 after purchasing an additional 10,165 shares during the period. Larson Financial Group LLC grew its position in shares of Corteva by 2.8% in the fourth quarter. Larson Financial Group LLC now owns 34,492 shares of the company’s stock valued at $2,312,000 after purchasing an additional 942 shares during the period. Handelsbanken Fonder AB increased its position in Corteva by 7.6% during the fourth quarter. Handelsbanken Fonder AB now owns 402,845 shares of the company’s stock worth $27,003,000 after purchasing an additional 28,517 shares during the last quarter. ProShare Advisors LLC boosted its holdings in Corteva by 10.8% in the 4th quarter. ProShare Advisors LLC now owns 146,416 shares of the company’s stock valued at $9,814,000 after purchasing an additional 14,257 shares during the last quarter. Finally, HighTower Advisors LLC grew its position in Corteva by 5.7% in the fourth quarter. HighTower Advisors LLC now owns 193,070 shares of the company’s stock worth $12,941,000 after acquiring an additional 10,427 shares during the period. Hedge funds and other institutional investors own 81.54% of the company’s stock.

Corteva News Summary

Here are the key news stories impacting Corteva this week:

• Positive Sentiment: RBC raised its price target to $89 and kept an “outperform” rating — a bullish analyst signal that implies ~23% upside from the recent price. RBC raises price target
• Positive Sentiment: Consensus broker view listed as “Moderate Buy,” reflecting broad analyst support that can help underpin the stock. Consensus Moderate Buy
• Neutral Sentiment: Coverage piece argues the bull case for Corteva could shift after developments in a Bayer settlement and licensing arrangements — potential structural implications but outcome and timing remain uncertain. Bull case and Bayer/licensing
• Neutral Sentiment: Report noting conflicting analyst views — some upgrading targets, others trimming ratings — highlighting divergence in expectations for growth and valuation. Conflicting analyst sentiments
• Neutral Sentiment: CFO/management commentary and the earnings presentation highlighted record free cash flow and strategic execution, positive fundamentals that may temper the headline revenue miss. Earnings call highlights
• Negative Sentiment: Q4 revenue missed estimates due to seasonal timing shifts and lower crop-protection and seed demand; the miss caused shares to fall in after-hours trading. This direct earnings disappointment is the primary near-term negative catalyst. Revenue miss and seasonality
• Negative Sentiment: JPMorgan downgraded Corteva from “overweight” to “neutral,” citing valuation and limited near-term upside despite a slightly higher $77 target — another headwind to sentiment. JPMorgan downgrade

About Corteva

Corteva, Inc (NYSE: CTVA) is an independent global agriculture company that was established as a publicly traded firm in mid‑2019 following the separation of the agriculture businesses from DowDuPont. The company focuses on delivering technologies and products that help farmers increase productivity and manage crop health. Corteva’s operations combine seed genetics, crop protection chemistries, digital tools and biological solutions to address the full cycle of crop production.

Core business activities include research and development of seed genetics and trait technologies, formulation and sale of crop protection products (such as herbicides, insecticides and fungicides), and the development of seed treatments and biologicals.